News Releases

Date	Title
09/22/23	Optinose to Present at the 2023 Cantor Global Healthcare Conference
08/10/23	Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
07/27/23	Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
06/16/23	Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/02/23	Optinose to Present at the Jefferies Healthcare Conference
05/11/23	Optinose Reports First Quarter 2023 Financial Results and Operational Updates
05/04/23	Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
05/01/23	Optinose Announces Reporting Date for First Quarter 2023 Financial Results
04/18/23	Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/12/23	Optinose to Present at the Needham Virtual Healthcare Conference
03/07/23	Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
02/28/23	Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
02/21/23	Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
01/31/23	Optinose Announces CEO Transition and Business Update

Keyword Search